TLSA Stock Chart & Stats
$1.09
-$0.13(-12.50%)
At close: 4:00 PM EDT
$1.09
-$0.13(-12.50%)
Day’s Range― - ―
52-Week Range$0.87 - $2.35
Previous Close$0.91
Volume328.81K
Average Volume (3M)893.20K
Market Cap
$123.64M
Enterprise Value-$65.27M
Total Cash (Recent Filing)$4.01M
Total Debt (Recent Filing)$456.00K
Price to Earnings (P/E)―
Beta-0.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding128,309,130
10 Day Avg. Volume918,978
30 Day Avg. Volume893,199
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.69K
Price to Sales (P/S)0.00
P/FCF Ratio-6.85
Enterprise Value/Market Cap-0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit278.93
Enterprise Value/Ebitda3.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)N/A
Tiziana Life Sciences News
TLSA FAQ
What was Tiziana Life Sciences Plc’s price range in the past 12 months?
Tiziana Life Sciences Plc lowest stock price was $0.87 and its highest was $2.35 in the past 12 months.
What is Tiziana Life Sciences Plc’s market cap?
Tiziana Life Sciences Plc’s market cap is $123.64M.
When is Tiziana Life Sciences Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tiziana Life Sciences Plc’s earnings last quarter?
Tiziana Life Sciences Plc released its earnings results on Sep 24, 2021. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.142.
Is Tiziana Life Sciences Plc overvalued?
According to Wall Street analysts Tiziana Life Sciences Plc’s price is currently Overvalued.
Does Tiziana Life Sciences Plc pay dividends?
Tiziana Life Sciences Plc does not currently pay dividends.
What is Tiziana Life Sciences Plc’s EPS estimate?
Tiziana Life Sciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tiziana Life Sciences Plc have?
Tiziana Life Sciences Plc has 128,309,130 shares outstanding.
What happened to Tiziana Life Sciences Plc’s price movement after its last earnings report?
Tiziana Life Sciences Plc reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Tiziana Life Sciences Plc?
Currently, no hedge funds are holding shares in TLSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tiziana Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TLSA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tiziana Life Sciences Plc
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Technical Analysis
Ownership Overview
73.84% Insiders
0.10% Mutual Funds
1.31% Other Institutional Investors
24.75% Public Companies and
Individual Investors